Gabapentin bioavailability: Effect of dose and frequency of administration in adult patients with epilepsy

Epilepsy Research

Volumn 31, Issue 2, 1998, Pages 91-99

  Gidal, Barry E ^a,b   DeCerce, John ^c   Bockbrader, Howard N ^d   Gonzalez, Jose ^c   Kruger, Sarah ^b   Pitterle, Michael E ^a   Rutecki, Paul ^b   Ramsay, R Eugene ^c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d PFIZER INC   (United States)

Author keywords

Bioavailability; Epilepsy; Gabapentin

Indexed keywords

ANTICONVULSIVE AGENT; GABAPENTIN;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; EPILEPSY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEADY STATE;

ACETIC ACIDS; ADULT; AMINES; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; CYCLOHEXANECARBOXYLIC ACIDS; EPILEPSY; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED;

EID: 0031858744     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(98)00020-5     Document Type: Article

References (12)

1. Bockbrader H.N. Clinical pharmacokinetics of gabapentin. Drugs Today. 31:1995;613-619.
2. Bockbrader H.N., Breslin E.M., Underwood B.A., Posvar E.L., Sedman A.J. Multiple-dose, dose-proportionality study of Neurontin (gabapentin) in health volunteers. Epilepsia. 37(5):1996;159.
3. Cramer J.A., Mattson R.H., Prevey M.L.et al. How often is medication taken as prescribed? A novel assessment technique. J. Am. Med. Assoc. 261:1989;3273-3277.
4. Gilbaldi, M., Perrier, D. (Eds.), 1975. Pharmacokinetics, vol. 1. Marcel Decker, New York.
5. Heinzel, G., Woloszczak, R., Thomann, P., 1993. Topfit version 2.0: Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC. Fischer, Stuttgart.
6. Hellriegel E.T., Bjornsson T.D., Hauck W.W. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin. Pharmacol. Ther. 60:1996;601-607.
7. Lensmeyer G., Kempf T., Gidal B., Weibe D. Optimized method for determination of gabapentin in serum by HPL. Ther. Drug Monit. 17:1995;251-258.
8. McLean M.J. Clinical pharmacokinetics of gabapentin. Neurology. 44:1994;S17-S22.
9. Stevenson C.M., Radulovic L.L., Bockbrader H.N., Fleisher D. Contrasting nutrient effects on the plasma levels of an amino acid like antiepileptic agent from the jejunal administration in dogs. J. Pharm. Sci. 86:1997;953-957.
10. Stevenson C.M., Kim J., Fleisher D. Colonic absorption of antiepileptic agents. Epilepsia. 38:1997;63-67.
11. Stewart B.H., Kugler A.R., Thompson P.R., Bockbrader H.N. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm. Res. 10:1993;276-282.
12. Vollmer K.O., Anhut H., Thomann P., Wagner F., Jaehnchen D. Pharmacokinetic model and absolute bioavailability of the new anticonvulsant gabapentin. Adv. Epileptol. 17:1989;209-211.